<DOC>
	<DOCNO>NCT02962102</DOCNO>
	<brief_summary>The purpose study assess efficacy calcifediol ( 25-hydroxyvitamin D ) calcitriol ( 1,25-dihydroxyvitamin D ) prevent reduce severity acute kidney injury ( AKI ) critically ill patient .</brief_summary>
	<brief_title>Activated Vitamin D Prevention Treatment Acute Kidney Injury</brief_title>
	<detailed_description />
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Critical Illness</mesh_term>
	<mesh_term>Acute Kidney Injury</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<mesh_term>Calcifediol</mesh_term>
	<criteria>Age ≥ 18 Admitted ICU within 48h prior enrollment Likely remain ICU ( alive ) ≥72h Naso/orogastric tube ability swallow High risk severe AKI Serum total calcium &gt; 9.0 mg/dl phosphate &gt; 6.0 mg/dL within previous 48h Currently receive oral calcium supplementation Ingestion vitamin D3 &gt; 1,000 IU/day 25hydroxyvitamin D 1,25dihydroxyvitamin D previous 7 day AKI stage 2 3 ( base KDIGO serum creatinine and/or urine output criterion ) History transplantation receive immunosuppressive medication ( include glucocorticoid steroid dose less equivalent prednisone 20 mg/day ) Neutropenia previous 48h Active primary parathyroid disease , active granulomatous disease , symptomatic nephrolithiasis previous 3 month Receiving cytochrome P450 inhibitor Chronic Kidney Disease stage V End Stage Renal Disease Hemoglobin &lt; 7 g/dL GI malabsorption Prisoner Pregnancy breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>